Craig M. Crews
- Hematology top 0.05%
- Multiple Myeloma Research and Treatments 29
- Oncology top 0.05%
- Peptidase Inhibition and Analysis 61
- Molecular Biology top 0.05%
- Ubiquitin and proteasome pathways 106
- Protein Degradation and Inhibitors 106
- Signaling Pathways in Disease 14
- Histone Deacetylase Inhibitors Research 13
- Cell Biology top 0.5%
- Cancer Research top 1%
-
- Prostate Cancer Treatment and Research 14
-
- Synthetic Organic Chemistry Methods 11
- Co-authors
- Raymond L. EriksonGeorge M. BurslemMiklós BékésDavid R. LangleyJohn HinesMomar ToureRaymond J. DeshaiesKathleen M. Sakamoto
- Cited by
- HematologyOncologyMolecular Biology
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Craig M. Crews
204 papers receiving 31.3k citations
Hit Papers
Peers
Comparison fields: 5 of 151
- Hematology 5.6k
- Oncology 11.2k
- Molecular Biology 27.8k
- Cell Biology 1.9k
- Cancer Research 1.5k
Countries citing papers authored by Craig M. Crews
This map shows the geographic impact of Craig M. Crews's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig M. Crews with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig M. Crews more than expected).
Fields of papers citing papers by Craig M. Crews
This network shows the impact of papers produced by Craig M. Crews. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig M. Crews. The network helps show where Craig M. Crews may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Craig M. Crews, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 18 | |
| 2 | 2024 | 12 | |
| 3 | Protein degraders enter the clinic — a new approach to cancer therapybreakdown → | 2023 | 375 |
| 4 | 2021 | 105 | |
| 5 | 2021 | 124 | |
| 6 | Targeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACsbreakdown → | 2020 | 313 |
| 7 | 2020 | 30 | |
| 8 | 2019 | 165 | |
| 9 | 2019 | 232 | |
| 10 | 2019 | 56 | |
| 11 | 2018 | 32 | |
| 12 | 2017 | 1 | |
| 13 | 2017 | 220 | |
| 14 | 2016 | 19 | |
| 15 | 2016 | 8 | |
| 16 | 2014 | 80 | |
| 17 | 2007 | 202 | |
| 18 | 2006 | 11 | |
| 19 | 2003 | 258 | |
| 20 | 2000 | 88 |
About Craig M. Crews
Craig M. Crews is a scholar working on Oncology, Hematology and Molecular Biology, having authored 209 papers that have together received 32.0k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (106 papers), Protein Degradation and Inhibitors (106 papers), Peptidase Inhibition and Analysis (61 papers), Multiple Myeloma Research and Treatments (29 papers), Signaling Pathways in Disease (14 papers), Prostate Cancer Treatment and Research (14 papers), Histone Deacetylase Inhibitors Research (13 papers) and Synthetic Organic Chemistry Methods (11 papers). The work is most often cited by research in Hematology (5.6k citations), Oncology (11.2k citations) and Molecular Biology (27.8k citations). Craig M. Crews has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Raymond L. Erikson, George M. Burslem, Miklós Békés, David R. Langley, John Hines, Momar Toure, Raymond J. Deshaies, Kathleen M. Sakamoto, Alessandro Alessandrini and Timothy W. Corson. Their work appears in journals such as Nature, Science and Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.